TG Therapeutics (NASDAQ: TGTX) is Poised For Break Out on a HUGE Catalyst – Could Soar 26%

We flagged TG Therapeutics, Inc. (NASDAQ: TGTX) in our breakout watchlist a few weeks back — and the stock has since almost broken out of a two-month symmetrical triangle and looks headed even higher.

As we’ll get to just ahead, the combination of accelerating sales momentum with a fresh guidance raise, a pair of major clinical wins that could dramatically expand the reach of its flagship drug, and a fresh technical breakout makes TGTX one of the more interesting setups on the board. Here’s what’s going on…

The Themes Behind the Move

TG Therapeutics is a U.S.-based commercial-stage biotech focused on treating B-cell mediated diseases, with its flagship drug BRIUMVI — an intravenous anti-CD20 antibody approved for adults with relapsing forms of multiple sclerosis (RMS). Its development pipeline extends into a subcutaneous version of BRIUMVI, a BTK inhibitor (TG-1701), a bispecific CD47/CD19 antibody (TG-1801), and additional programs in myasthenia gravis and progressive MS.

In plain English, when a patient with multiple sclerosis needs an infusion-based therapy that reduces relapses and slows disease progression, BRIUMVI is one of the newest approved options — designed to be delivered faster than the older anti-CD20 competitors. Its business hinges on continued market-share gains against entrenched incumbents like Roche’s Ocrevus and Novartis’ Kesimpta, on the payoff from a Phase 3 program aimed at simplifying dosing and opening a self-administered market, and on adjacent pipeline programs that could broaden the disease portfolio over time.

TGTX’s latest move reflects a powerful confluence of developments — clinical, commercial, and operational — that have come together in rapid succession to fundamentally reframe the company’s near-term growth trajectory.

If needed, swipe or scroll sideways to view the full table.

Put it all together, and TGTX is looking less like a one-product biotech leaning on hope and more like a commercially executing MS franchise with a rapidly ramping U.S. product, a Phase 3 win already in hand, and a pivotal subcutaneous readout on deck that could unlock a major new addressable market.

The story is getting stronger, but the chart is what could determine whether this move has more room to run in the near term. Here are the bullish technical signals traders should be watching now.

Bullish Technical Signals

#1 Symmetrical Triangle Near Breakout : TGTX has spent roughly two months coiling inside a symmetrical triangle — converging trendlines built from lower highs (rolling off the early-July peak near $56) and higher lows (rising from the August low near $48), marked in purple. That compression reflects a tightening equilibrium between buyers and sellers, and symmetrical triangles historically resolve in the direction of the trend that preceded them — here, the powerful March–July advance that carried the stock from ~$28 to ~$56. Price is now pressing the upper rail, and today’s +5.30% session ($2.81 to a $55.85 close, intraday high $57.61) is the thrust resolving the coil to the upside. The break carries added significance because it’s firing at the apex, where the pattern has wound to its tightest — apex breakouts tend to release the most stored energy. The one honest caveat: volume on the move (2.35M) is supportive but not explosive, so the confirmation to watch is a decisive close above ~$57 on sustained participation rather than a single-bar spike.

TGTX – Daily Chart

#2 Price Above 50 & 200-Day SMAs: TGTX trades above both its 50-day SMA ($53.51) and 200-day SMA ($39.82), with the 50-day stacked well above the 200-day — the golden-cross alignment confirming momentum points up across both short- and long-term horizons. Both averages slope positively, and the wide gap between them (~$14) reflects a trend that has been building for months, not one just getting underway. What makes the current position especially clean is that price sits right on top of the rising 50-day rather than stretched far above it — the stock is not extended, so the risk here is unusually well-defined. That proximity turns the 50-day ($53.51) into an immediate dynamic-support shelf, with the $52 stop sitting just beneath it: a slip back through that zone breaks structure, while any hold above keeps the tiered support (50-day ~$53.51, then 200-day ~$40) intact beneath the breakout.

#3 Bullish Stochastic: The daily stochastic shows %K (58.81) crossed above %D (34.38) — and critically, it’s a mid-range cross, not an oversold one. That distinction matters: in an established uptrend, mid-range stochastic crossovers are the higher-quality signal, because they show momentum re-accelerating out of a healthy consolidation rather than a desperate bounce off the lows. The wide separation between the two lines (~24 points) tells you the turn has conviction behind it, not a hesitant flicker. And with %K at 58.81, there’s clear runway before the oscillator reaches the overbought 80 zone — momentum is expanding into open space rather than firing into resistance. Stacked against the triangle breakout, the stochastic corroborates the price action rather than diverging from it.

#4 Bullish ADX and DI: The ADX configuration is a textbook early-trend read. First, +DI (29.96) sits well above –DI (14.90) — a spread of roughly 15 points that places directional control firmly with buyers, not a narrow tilt that could flip on a single down day. Second, the ADX line (23.63) is rising up between the two DI lines, having lifted off a suppressed base beneath both. Because ADX is direction-agnostic and measures only trend strength, a rise from a low reading is the indicator’s way of signaling that a new trend isn’t just forming but gathering force. The constructive part is that ADX is still below the 25 threshold — the conventional line between a rangebound and a trending market — while inflecting higher: that means this move is in its early innings with runway ahead, rather than a mature trend approaching exhaustion. Combined with the triangle breakout and the stochastic cross, all three daily reads point the same direction.

#5 Above Support with Price Over Weekly MAs: Zooming out reframes the daily breakout within a much larger structure. On the weekly chart, TGTX has held and lifted off a resistance-turned-support level at $51.25 (the pink dotted line) — a polarity flip where a former ceiling now acts as a floor, exactly the kind of level the market respects most. Recent weekly candles tested that zone (this week’s low $52.50) and recovered, confirming buyers are actively defending it. Price also trades far above both the rising 50-week SMA ($39.01) and 200-week SMA ($26.64), with the 50-week well above the 200-week — the same golden-cross alignment seen on the daily, now validated on the higher timeframe. That multi-timeframe agreement is the point: the daily triangle is breaking out from directly atop a weekly support shelf, so both timeframes tell the same story — and when daily and weekly align, the signal carries more weight than either alone.

TGTX – Weekly Chart

#6 Bullish RSI: The weekly RSI (63.45) sits comfortably above its 50 midline, holding in the upper, bullish half of its range — confirming that buying momentum structurally outweighs selling pressure on the higher timeframe. At ~63, RSI is firmly bullish but still short of the overbought 70 threshold, which leaves runway before the indicator itself becomes a headwind. The honest nuance worth flagging: RSI has ticked slightly below its own signal average (66.76), a sign near-term momentum has cooled marginally even as the structural read stays intact. That’s a minor consolidation within a bullish regime, not a reversal — a fresh push back above the signal line would re-confirm momentum is re-expanding rather than stalling. On balance, the weekly RSI keeps the higher-timeframe momentum backdrop supportive of the daily breakout.

#7 Bullish TRIX: The weekly TRIX — a triple-smoothed momentum oscillator engineered to strip out short-term noise — is holding above its zero line and curling higher after a shallow dip. This carries weight precisely because TRIX is deliberately slow: it doesn’t react to minor fluctuations, so when it stays positive and turns up, it’s confirming that the underlying trend, filtered of week-to-week volatility, remains pointed higher. A position above zero means the smoothed rate of change is positive — momentum is compounding, not fading — and the upward inflection signals that the brief cooling seen in the RSI hasn’t dented the primary trend. As the slowest of the three weekly reads, TRIX functions as the structural anchor: it tells us the multi-year uptrend that carried TGTX off its lows is still fundamentally intact, giving the faster daily signals a durable backdrop to fire against.

Risks to Consider

Even strong setups can fail, especially in a single-franchise biotech like TG Therapeutics. A few things could knock the stock off course:

• A breakdown back below the symmetrical triangle support on heavy volume would invalidate the breakout thesis
• Negative company-specific news, broader market weakness, or any regulatory shift affecting the anti-CD20 class would pressure the stock
• Single-franchise concentration — BRIUMVI drives essentially the entire commercial thesis, so any safety, reimbursement, or share-loss setback would disproportionately hit revenue and valuation
• Formidable competition from Roche’s Ocrevus and Ocrevus Zunovo and Novartis’ Kesimpta — both of which already offer subcutaneous administration, with prospective Ocrevus biosimilars a longer-term pricing risk across the class
• Binary clinical/regulatory risk — the pivotal Phase 3 subcutaneous BRIUMVI readout is a make-or-break moment for a program that increasingly matters to valuation; disappointing data or regulatory delays could trigger an outsized share-price reaction
• Valuation and operating leverage — shares closed September 16 at $55.85, close to the $59.30 52-week high after a big 2026 rally, and current GAAP profitability remains modest as TG invests heavily in manufacturing and pipeline expansion, per the Q2 2026 10-Q
• Elevated short interest at 21.6% of float reflects substantial disagreement around the equity and can amplify both positive and negative catalyst reactions
• Takeover-rumor premium — August acquisition chatter is unconfirmed, and any premium attached to a possible deal can unwind if no transaction emerges; a modest recent insider Form 4 also disclosed a 5,000-share sale (tax-related and non-discretionary, per the filing)

The Bottom Line

TGTX is breaking out of a two-month symmetrical triangle on the daily chart while holding above a key resistance-turned-support level on the weekly — a dual-timeframe technical setup that historically signals the start of a sustained move higher.

The fundamental story underneath the chart is just as strong: BRIUMVI revenue up ~64% year-over-year in Q2 with raised FY2026 guidance to ~$950 million, a successful Phase 3 trial simplifying BRIUMVI’s IV dosing regimen, and a pivotal Phase 3 subcutaneous BRIUMVI readout on deck by year-end.

Combine that with multiple commercial and clinical catalysts staggered through the back half of 2026 and into 2027 — a supplemental FDA filing, Q3 earnings in early November, additional pipeline readouts, and the transformative subcutaneous data — and TGTX looks like one of the more compelling risk-reward setups on the board right now.

If this is a trade you want to get in on, here’s how we’d play it. Below you’ll find our exact entry level, both price targets that imply 18%–26% potential upside, and the stop-loss we’re using to manage the downside.

Recommended Trade Setup

If needed, swipe or scroll sideways to view the full table.

For a risk of approximately $5.00 per share, the target rewards are about $10.00 and $15.00 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.

Note on Trade Invalidation: This recommendation stays active as long as the technical structure holds. If TGTX drops to or below the $52.00 stop-loss before the $57.00 entry triggers, the trade is automatically void — the support underpinning the thesis would have broken, and the risk-reward setup would no longer justify entry.

Happy Trading!
Tara and Greg